The neonatal adverse event severity scale: current status, a stakeholders' assessment, and future perspectives

The neonatal adverse event severity scale: current status, a stakeholders' assessment, and future perspectives

To support informed decisions on drug registration and prescription, clinical trials need tools to assess the efficacy and safety signals related to a given therapeutic intervention. Standardized assessment facilitates reproducibility of results. Furthermore, it enables weighted comparison between d...

Full description

Bibliographic Details
Main Authors: Karel Allegaert, Thomas Salaets, Kelly Wade, Mary A. Short, Robert Ward, Kanwaljit Singh, Mark A. Turner, Jonathan M. Davis, Tamorah Lewis
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Pediatrics
Subjects:
newborn
infant
clinical trials
data standards
drug development
drug safety
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2023.1340607/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2023.1340607/full

Similar Items